Zalevsky Jonathan's Form 4 filing
Nektar Therapeutics (NKTR) · filed Sep 8, 2025
- Accession no.
- 0000950170-25-113692
- Filed
- Sep 8, 2025
- Trade date
- Sep 4, 2025
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Checked
This filing lists 4 non-derivative transactions and 0 derivative transactions. Open-market sales total $57.7K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Zalevsky JonathanCIK 0001789857 | Officer (Chief R&D Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 4, 2025 | Common Stock | SSaleDisposed | −793 | $32.43 | −$25,716.99 | 18,390 | Direct | |
| Sep 4, 2025 | Common Stock | SSaleDisposed | −432 | $33.60 | −$14,515.2 | 17,958 | Direct | |
| Sep 4, 2025 | Common Stock | SSaleDisposed | −189 | $34.41 | −$6,503.49 | 17,769 | Direct | |
| Sep 4, 2025 | Common Stock | SSaleDisposed | −307 | $35.69 | −$10,956.83 | 17,462 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.